Skip to main content
Premium Trial:

Request an Annual Quote

Illumina VeriSeq NIPT Solution v2

Illumina has launched the VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing-based approach to noninvasive prenatal testing. The new version expands the range of chromosomal and sub-chromosomal conditions associated with birth defects that laboratories can screen for. The assay provides information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw, and provides an option to screen for aneuploidy in all autosomes, chromosomes X & Y, and partial deletions and duplications greater than 7 Mb across the genome. It is available in Europe and South Africa; registration is pending in Australia, Israel, and New Zealand.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.